Lupin receives FDA approval for generic prilosec capsules

It is indicated for the short-term treatment of duodenal ulcer, gastric ulcer and treatment of GERD

Lupin has received final approval for its Omeprazole delayed-release capsules 40 mg from the United States Food and Drugs Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals (AstraZeneca) Prilosec delayed-release capsules 40mg.

Lupin’s Omeprazole delayed-release capsules 40 mg are the AB rated generic equivalent of AstraZeneca’s Prilosec delayed-release capsules 40mg. It is indicated for the short-term treatment of duodenal ulcer, gastric ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), maintenance of healing of erosive esophagitis and pathological hypersecretory conditions.